Cardiovascular health is evolving as an important consideration in patients with CML, not only because of the improved prognosis being enjoyed by patients treated with TKI-based therapies, but also because some later-generation BCR::ABL1 TKIs have been associated with cardiovascular complications [27]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.